Figure 3.

Disease onset and progression are delayed in SOD1‐G93A mice by targeting both astrocytes and microglia. (A) Uninjected CSF1R‐cre+ mice (blue) retained more body mass in late stages of disease compared to uninjected CSF1R‐cre− mice (red). P21‐treated mice, both CSF1R‐cre− (gray) and CSF1R‐cre+ (green), maintained body mass throughout their increased lifespan (B) Onset defined by peak weight is delayed in CSF1R‐cre+; p21 injected mice (green) compared to all uninjected (blue and green) and CSF1R‐cre−; p21 injected mice (gray). (C) Disease progression, defined by time from peak weight until death, is delayed in all mice with either microglia (blue), astrocytes (gray), or both (green) targeted, compared to untreated controls (red). ***p < 0.001; ****p < 0.0001.